Company news

Paradigm Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA provides key path toward phase 3 trials and registration

September 27, 2020

Paradigm Presentation to Emerging Leaders Conference

September 16, 2020

Appendix 4E and 2020 Annual Report

August 27, 2020

MPS receives critical approvals and feedback from agencies

August 10, 2020

Quarterly Activities Report

July 31, 2020

EAP - 65% pain reduction in 10 OA patients in usa

July 29, 2020

New financial year update

July 15, 2020

S&P DJI Announces June 2020 Quarterly Rebalance

June 11, 2020

Block trade to institutional investors

May 12, 2020

EAP treatment completed and Orphan Status achieved for MPS-I

April 30, 2020

Reinstatement to Official Quotation

April 8, 2020

Paradigm completes $35m raising

April 7, 2020

Paradigm Reports Very Encouraging Real World Data

April 6, 2020

Paradigm receives clarity on US regulatory pathway

April 5, 2020

Paradigm Latest Corporate Presentation

April 5, 2020

Voluntary Suspension

April 5, 2020

All 10 participants in US FDA EAP have commenced treatment

March 23, 2020

Paradigm reports Positive Pre-IND meeting with US FDA

February 20, 2020

Paradigm - first patient dosed in USA under FDA approved EAP

February 17, 2020

Paradigm presents MPS VI poster at WORLD Symposium

February 12, 2020

Cleansing Notice and Appendix 3B

December 18, 2019

Paradigm End of Calendar Year Update

December 11, 2019

Paradigm AGM Presentation

November 7, 2019

Paradigm provides regulatory filing update

October 24, 2019

Osteoarthritis pain reduced by Paradigms Zilosul (PPS)

September 29, 2019

PAR Expanded Access IND Cleared by US FDA

September 10, 2019

Appendix 4E and 2019 Annual Report

August 30, 2019

PARs drug reduces cartilage degradation in subjects with OA

August 28, 2019

Paradigm files first IND with US FDA

August 6, 2019

Appendix 4C - quarterly

July 31, 2019

Paradigm EOFY Update

June 28, 2019

PAR reports successful Ross River phase 2 clinical trial

June 3, 2019

PAR reports consistent pain reduction in knee OA of patients

May 27, 2019

PAR corrects AFR article

May 21, 2019

Successful Completion of Retail Entitlement Offer

May 8, 2019

Paradigm Corporate Update - May 2019

May 7, 2019

Quarterly Report and Appendix 4C - quarterly

April 30, 2019

Completion of Institutional Entitlement Offer

April 23, 2019

PAR Accelerated Non-Renounceable Rights Issue Offer Booklet

April 16, 2019

Paradigm Confirms Capital Raise Commitments

April 16, 2019

Paradigm updated corporate presentation

April 14, 2019

Paradigm launches a$77.9M capital raise

April 14, 2019

Paradigms secondary endpoints successfully met

April 14, 2019

Paradigm (PAR) Updated Investor Presentation

March 12, 2019

S&P DJI Announces March 2019 Quarterly Rebalance

March 7, 2019

Paradigms orphan Phase 2/3 clinical program progresses

February 13, 2019

Paradigms supplementary Phase 2B data

December 19, 2018

Presentation of Phase 2 clinical trial results

December 17, 2018

PAR reports successful Phase 2 clinical trial

December 17, 2018

Paradigm reports consistent OA pain reduction

December 6, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 30 decks. Every deck is listed under its year.